Oncology Central republishes press releases that fall within our scope and provide value to its readers and the wider community.

Press release sourcing

Oncology Central utilizes established, reputable news release distribution services (e.g., EurekAlert, ScienceDaily) to source press releases.

Oncology Central has established strong relationships with press and media contacts at leading universities and research institutes. This network ensures our in-house editorial team has access to the latest and most newsworthy press releases, helping keep the publication at the forefront of cancer developments.

Press releases are reviewed by the editorial team to determine their suitability for publication.

In-house review process

The selection of press releases is at the discretion of Oncology Central’s editorial team. Each press release is reviewed by an editor to ensure it aligns with Oncology Central’s coverage and meets the necessary publication criteria.

Requirements for publication

All press releases must meet the following criteria:

  • Attribution and reader transparency– The source of the press release must be easily identifiable, and a link must be provided to allow Oncology Central to attribute it correctly.
  • Objective tone– Press releases must be unbiased and should avoid first-person/direct address (‘you’, ‘I’, ‘we’, etc.) unless used within a direct quotation from an interviewee who is appropriately positioned to comment on the details of the story.
  • Newsworthy, timely and relevant– Oncology Central republishes press releases that focus on the latest research, therapeutic developments and business news in oncology. Examples include:
    • Research carried out by academic institutions and leading research organizations.
    • Biopharma and pharma developments (e.g., regulatory approvals/recalls, pre/clinical progress)
    • Industry events (e.g., trade shows, conferences, etc.)
    • Awards/prizes or industry recognition
    • Major milestones in science and medicine
  • Language, spelling and grammar– Press releases are republished in both UK and US English. While BioTechniques produces all original website content in US English, press release copy originally written in UK English will not be edited to conform to our in-house style. In-house style changes are only applied to the press release headline and summary text featured on the news listing page.
  • Precise and factual– We operate under the assumption that the information contained in a press release is both legally and factually accurate, having undergone review before publication. Oncology Central does not conduct extensive fact-checking of press releases prior to their republishing. Nonetheless, we are committed to making necessary edits. If you have feedback, please submit it through our Contact Us

Original source attribution

Oncology Central clearly attributes the original source of each press release at the start of the republished press release by displaying the following text: ‘Original story from [original source]’. This attribution is linked to the source’s homepage.

The following disclaimer is included at the end of the republished release.

This article has been republished from the following materials. Material may have been edited for length and to follow our house style. For further information, please contact the cited source. Our press release publishing policy can be accessed here.

If the press release pertains to a research paper, this will be referenced at the end of the release, to allow readers to access it via the journal’s website. If a preprint is referenced in the press release, the following disclaimer will be included:

This article is based on research findings that are yet to be peer-reviewed. Results are therefore regarded as preliminary and should be interpreted as such. For further information, please contact the cited source.

Story headline and imagery

To maintain consistency with its in-house style, Oncology Central customizes the headlines of republished press releases.

Oncology Central ensures that it has the necessary permissions to use any related imagery accompanying press releases and will credit accordingly. If there's any uncertainty regarding image rights, Oncology Central will source an alternative image that aligns with the theme of the press release.